Transcription factor Zfx regulates tumor’s evasion to T cell killing in immunotherapy
Year: 2025
Type: article
Abstract: . We demonstrate that Zfx regulates expression of the apoptotic machinery, with Caspase-3 being a central element in mediating T cell killing. Mechanistically, our ChIP-Seq analyses in multiple human cancer cell lines show ZFX directly binds to the promoters of key apoptosis genes, including Caspase-3, to control their expression. Notably, ZFX expression is decreased in several human cancer tissues compared to healthy tissues. Female patients with kidney renal clear cell carcinoma (KIRC) with high ZFX expression showed longer survival compared to patients with low ZFX expression. In addition, we find that higher ZFX expression in patients with melanoma correlates with a positive response to anti-PD-1 immunotherapy. Our results demonstrate a novel resistant mechanism in tumor cells, highlighting ZFX as a potential biomarker for immunotherapy response, and suggest that targeting tumor cell intrinsic resistance genes in combination with immune therapies could benefit patients with cancer.
Source: iScience
Authors: Ulrike Kaufmann, Joy Wang, Marinella G. Callow, Jean-Philippe Fortin, Szymon Myrta, Dorothee Nickles, Rohit Reja, Eric Cheng, Erin Wonder, Benjamin Haley, Yuxin Liang, Scott Martin, Mike Costa, Haochu Huang
Institutions: Genentech, Roche (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,240
OpenAlex ID: W4415535802
